Correlation between Bioassay and Protein Misfolding Cyclic Amplification for Variant Creutzfeldt-Jakob Disease Decontamination Studies
To date, approximately 500 iatrogenic Creutzfeldt-Jakob disease cases have been reported worldwide, most of them resulting from cadaveric dura mater graft and from the administration of prion-contaminated human growth hormone. The unusual resistance of prions to decontamination processes, their larg...
Saved in:
| Published in | mSphere Vol. 5; no. 1 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Society for Microbiology
26.02.2020
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | To date, approximately 500 iatrogenic Creutzfeldt-Jakob disease cases have been reported worldwide, most of them resulting from cadaveric dura mater graft and from the administration of prion-contaminated human growth hormone. The unusual resistance of prions to decontamination processes, their large tissue distribution, and the uncertainty about the prevalence of variant Creutzfeldt-Jakob disease (vCJD) in the general population lead to specific recommendations regarding identification of tissue at risk and reprocessing of reusable medical devices, including the use of dedicated treatment for prion inactivation. We previously described an
assay, called Surf-PMCA, which allowed us to classify prion decontamination treatments according to their efficacy on vCJD prions by monitoring residual seeding activity (RSA). Here, we used a transgenic mouse line permissive to vCJD prions to study the correlation between the RSA measured
and the
infectivity. Implantation in mouse brains of prion-contaminated steel wires subjected to different decontamination procedures allows us to demonstrate a good concordance between RSA measured by Surf-PMCA (
) and residual infectivity (
). These experiments emphasize the strength of the Surf-PMCA method as a rapid and sensitive assay for the evaluation of prion decontamination procedures and also confirm the lack of efficacy of several marketed reagents on vCJD prion decontamination.
Creutzfeldt-Jakob diseases are neurodegenerative disorders for which transmission linked to medical procedures have been reported in hundreds of patients. As prion diseases, they are characterized by an unusual resistance to conventional decontamination processes. Moreover, their large tissue distribution and the ability of prions to attach to many surfaces raised the risk of transmission in health care facilities. It is therefore of major importance that decontamination procedures applied to medical devices before their reprocessing are thoroughly validated for prion inactivation. We previously described an
assay, which allowed us to classify accurately prion decontamination treatments according to their efficacy on variant Creutzfeldt-Jakob disease. The significance of this study is in demonstrating the concordance between previous
results and infectivity studies in transgenic mice. Furthermore, commercial reagents currently used in hospitals were tested by both protocols, and we observed that most of them were ineffective on human prions. |
|---|---|
| AbstractList | To date, approximately 500 iatrogenic Creutzfeldt-Jakob disease cases have been reported worldwide, most of them resulting from cadaveric dura mater graft and from the administration of prion-contaminated human growth hormone. The unusual resistance of prions to decontamination processes, their large tissue distribution, and the uncertainty about the prevalence of variant Creutzfeldt-Jakob disease (vCJD) in the general population lead to specific recommendations regarding identification of tissue at risk and reprocessing of reusable medical devices, including the use of dedicated treatment for prion inactivation. We previously described an
assay, called Surf-PMCA, which allowed us to classify prion decontamination treatments according to their efficacy on vCJD prions by monitoring residual seeding activity (RSA). Here, we used a transgenic mouse line permissive to vCJD prions to study the correlation between the RSA measured
and the
infectivity. Implantation in mouse brains of prion-contaminated steel wires subjected to different decontamination procedures allows us to demonstrate a good concordance between RSA measured by Surf-PMCA (
) and residual infectivity (
). These experiments emphasize the strength of the Surf-PMCA method as a rapid and sensitive assay for the evaluation of prion decontamination procedures and also confirm the lack of efficacy of several marketed reagents on vCJD prion decontamination.
Creutzfeldt-Jakob diseases are neurodegenerative disorders for which transmission linked to medical procedures have been reported in hundreds of patients. As prion diseases, they are characterized by an unusual resistance to conventional decontamination processes. Moreover, their large tissue distribution and the ability of prions to attach to many surfaces raised the risk of transmission in health care facilities. It is therefore of major importance that decontamination procedures applied to medical devices before their reprocessing are thoroughly validated for prion inactivation. We previously described an
assay, which allowed us to classify accurately prion decontamination treatments according to their efficacy on variant Creutzfeldt-Jakob disease. The significance of this study is in demonstrating the concordance between previous
results and infectivity studies in transgenic mice. Furthermore, commercial reagents currently used in hospitals were tested by both protocols, and we observed that most of them were ineffective on human prions. To date, approximately 500 iatrogenic Creutzfeldt-Jakob disease cases have been reported worldwide, most of them resulting from cadaveric dura mater graft and from the administration of prion-contaminated human growth hormone. The unusual resistance of prions to decontamination processes, their large tissue distribution, and the uncertainty about the prevalence of variant Creutzfeldt-Jakob disease (vCJD) in the general population lead to specific recommendations regarding identification of tissue at risk and reprocessing of reusable medical devices, including the use of dedicated treatment for prion inactivation. We previously described an in vitro assay, called Surf-PMCA, which allowed us to classify prion decontamination treatments according to their efficacy on vCJD prions by monitoring residual seeding activity (RSA). Here, we used a transgenic mouse line permissive to vCJD prions to study the correlation between the RSA measured in vitro and the in vivo infectivity. Implantation in mouse brains of prion-contaminated steel wires subjected to different decontamination procedures allows us to demonstrate a good concordance between RSA measured by Surf-PMCA (in vitro) and residual infectivity (in vivo). These experiments emphasize the strength of the Surf-PMCA method as a rapid and sensitive assay for the evaluation of prion decontamination procedures and also confirm the lack of efficacy of several marketed reagents on vCJD prion decontamination. Creutzfeldt-Jakob diseases are neurodegenerative disorders for which transmission linked to medical procedures have been reported in hundreds of patients. As prion diseases, they are characterized by an unusual resistance to conventional decontamination processes. Moreover, their large tissue distribution and the ability of prions to attach to many surfaces raised the risk of transmission in health care facilities. It is therefore of major importance that decontamination procedures applied to medical devices before their reprocessing are thoroughly validated for prion inactivation. We previously described an in vitro assay, which allowed us to classify accurately prion decontamination treatments according to their efficacy on variant Creutzfeldt-Jakob disease. The significance of this study is in demonstrating the concordance between previous in vitro results and infectivity studies in transgenic mice. Furthermore, commercial reagents currently used in hospitals were tested by both protocols, and we observed that most of them were ineffective on human prions. To date, approximately 500 iatrogenic Creutzfeldt-Jakob disease cases have been reported worldwide, most of them resulting from cadaveric dura mater graft and from the administration of prion-contaminated human growth hormone. The unusual resistance of prions to decontamination processes, their large tissue distribution, and the uncertainty about the prevalence of variant Creutzfeldt-Jakob disease (vCJD) in the general population lead to specific recommendations regarding identification of tissue at risk and reprocessing of reusable medical devices, including the use of dedicated treatment for prion inactivation. We previously described an in vitro assay, called Surf-PMCA, which allowed us to classify prion decontamination treatments according to their efficacy on vCJD prions by monitoring residual seeding activity (RSA). Here, we used a transgenic mouse line permissive to vCJD prions to study the correlation between the RSA measured in vitro and the in vivo infectivity. Implantation in mouse brains of prion-contaminated steel wires subjected to different decontamination procedures allows us to demonstrate a good concordance between RSA measured by Surf-PMCA ( in vitro ) and residual infectivity ( in vivo ). These experiments emphasize the strength of the Surf-PMCA method as a rapid and sensitive assay for the evaluation of prion decontamination procedures and also confirm the lack of efficacy of several marketed reagents on vCJD prion decontamination. IMPORTANCE Creutzfeldt-Jakob diseases are neurodegenerative disorders for which transmission linked to medical procedures have been reported in hundreds of patients. As prion diseases, they are characterized by an unusual resistance to conventional decontamination processes. Moreover, their large tissue distribution and the ability of prions to attach to many surfaces raised the risk of transmission in health care facilities. It is therefore of major importance that decontamination procedures applied to medical devices before their reprocessing are thoroughly validated for prion inactivation. We previously described an in vitro assay, which allowed us to classify accurately prion decontamination treatments according to their efficacy on variant Creutzfeldt-Jakob disease. The significance of this study is in demonstrating the concordance between previous in vitro results and infectivity studies in transgenic mice. Furthermore, commercial reagents currently used in hospitals were tested by both protocols, and we observed that most of them were ineffective on human prions. ABSTRACT To date, approximately 500 iatrogenic Creutzfeldt-Jakob disease cases have been reported worldwide, most of them resulting from cadaveric dura mater graft and from the administration of prion-contaminated human growth hormone. The unusual resistance of prions to decontamination processes, their large tissue distribution, and the uncertainty about the prevalence of variant Creutzfeldt-Jakob disease (vCJD) in the general population lead to specific recommendations regarding identification of tissue at risk and reprocessing of reusable medical devices, including the use of dedicated treatment for prion inactivation. We previously described an in vitro assay, called Surf-PMCA, which allowed us to classify prion decontamination treatments according to their efficacy on vCJD prions by monitoring residual seeding activity (RSA). Here, we used a transgenic mouse line permissive to vCJD prions to study the correlation between the RSA measured in vitro and the in vivo infectivity. Implantation in mouse brains of prion-contaminated steel wires subjected to different decontamination procedures allows us to demonstrate a good concordance between RSA measured by Surf-PMCA (in vitro) and residual infectivity (in vivo). These experiments emphasize the strength of the Surf-PMCA method as a rapid and sensitive assay for the evaluation of prion decontamination procedures and also confirm the lack of efficacy of several marketed reagents on vCJD prion decontamination. IMPORTANCE Creutzfeldt-Jakob diseases are neurodegenerative disorders for which transmission linked to medical procedures have been reported in hundreds of patients. As prion diseases, they are characterized by an unusual resistance to conventional decontamination processes. Moreover, their large tissue distribution and the ability of prions to attach to many surfaces raised the risk of transmission in health care facilities. It is therefore of major importance that decontamination procedures applied to medical devices before their reprocessing are thoroughly validated for prion inactivation. We previously described an in vitro assay, which allowed us to classify accurately prion decontamination treatments according to their efficacy on variant Creutzfeldt-Jakob disease. The significance of this study is in demonstrating the concordance between previous in vitro results and infectivity studies in transgenic mice. Furthermore, commercial reagents currently used in hospitals were tested by both protocols, and we observed that most of them were ineffective on human prions. Creutzfeldt-Jakob diseases are neurodegenerative disorders for which transmission linked to medical procedures have been reported in hundreds of patients. As prion diseases, they are characterized by an unusual resistance to conventional decontamination processes. Moreover, their large tissue distribution and the ability of prions to attach to many surfaces raised the risk of transmission in health care facilities. It is therefore of major importance that decontamination procedures applied to medical devices before their reprocessing are thoroughly validated for prion inactivation. We previously described an in vitro assay, which allowed us to classify accurately prion decontamination treatments according to their efficacy on variant Creutzfeldt-Jakob disease. The significance of this study is in demonstrating the concordance between previous in vitro results and infectivity studies in transgenic mice. Furthermore, commercial reagents currently used in hospitals were tested by both protocols, and we observed that most of them were ineffective on human prions. ABSTRACT To date, approximately 500 iatrogenic Creutzfeldt-Jakob disease cases have been reported worldwide, most of them resulting from cadaveric dura mater graft and from the administration of prion-contaminated human growth hormone. The unusual resistance of prions to decontamination processes, their large tissue distribution, and the uncertainty about the prevalence of variant Creutzfeldt-Jakob disease (vCJD) in the general population lead to specific recommendations regarding identification of tissue at risk and reprocessing of reusable medical devices, including the use of dedicated treatment for prion inactivation. We previously described an in vitro assay, called Surf-PMCA, which allowed us to classify prion decontamination treatments according to their efficacy on vCJD prions by monitoring residual seeding activity (RSA). Here, we used a transgenic mouse line permissive to vCJD prions to study the correlation between the RSA measured in vitro and the in vivo infectivity. Implantation in mouse brains of prion-contaminated steel wires subjected to different decontamination procedures allows us to demonstrate a good concordance between RSA measured by Surf-PMCA ( in vitro ) and residual infectivity ( in vivo ). These experiments emphasize the strength of the Surf-PMCA method as a rapid and sensitive assay for the evaluation of prion decontamination procedures and also confirm the lack of efficacy of several marketed reagents on vCJD prion decontamination. IMPORTANCE Creutzfeldt-Jakob diseases are neurodegenerative disorders for which transmission linked to medical procedures have been reported in hundreds of patients. As prion diseases, they are characterized by an unusual resistance to conventional decontamination processes. Moreover, their large tissue distribution and the ability of prions to attach to many surfaces raised the risk of transmission in health care facilities. It is therefore of major importance that decontamination procedures applied to medical devices before their reprocessing are thoroughly validated for prion inactivation. We previously described an in vitro assay, which allowed us to classify accurately prion decontamination treatments according to their efficacy on variant Creutzfeldt-Jakob disease. The significance of this study is in demonstrating the concordance between previous in vitro results and infectivity studies in transgenic mice. Furthermore, commercial reagents currently used in hospitals were tested by both protocols, and we observed that most of them were ineffective on human prions. To date, approximately 500 iatrogenic Creutzfeldt-Jakob disease cases have been reported worldwide, most of them resulting from cadaveric dura mater graft and from the administration of prion-contaminated human growth hormone. The unusual resistance of prions to decontamination processes, their large tissue distribution, and the uncertainty about the prevalence of variant Creutzfeldt-Jakob disease (vCJD) in the general population lead to specific recommendations regarding identification of tissue at risk and reprocessing of reusable medical devices, including the use of dedicated treatment for prion inactivation. We previously described an in vitro assay, called Surf-PMCA, which allowed us to classify prion decontamination treatments according to their efficacy on vCJD prions by monitoring residual seeding activity (RSA). Here, we used a transgenic mouse line permissive to vCJD prions to study the correlation between the RSA measured in vitro and the in vivo infectivity. Implantation in mouse brains of prion-contaminated steel wires subjected to different decontamination procedures allows us to demonstrate a good concordance between RSA measured by Surf-PMCA (in vitro) and residual infectivity (in vivo). These experiments emphasize the strength of the Surf-PMCA method as a rapid and sensitive assay for the evaluation of prion decontamination procedures and also confirm the lack of efficacy of several marketed reagents on vCJD prion decontamination.IMPORTANCE Creutzfeldt-Jakob diseases are neurodegenerative disorders for which transmission linked to medical procedures have been reported in hundreds of patients. As prion diseases, they are characterized by an unusual resistance to conventional decontamination processes. Moreover, their large tissue distribution and the ability of prions to attach to many surfaces raised the risk of transmission in health care facilities. It is therefore of major importance that decontamination procedures applied to medical devices before their reprocessing are thoroughly validated for prion inactivation. We previously described an in vitro assay, which allowed us to classify accurately prion decontamination treatments according to their efficacy on variant Creutzfeldt-Jakob disease. The significance of this study is in demonstrating the concordance between previous in vitro results and infectivity studies in transgenic mice. Furthermore, commercial reagents currently used in hospitals were tested by both protocols, and we observed that most of them were ineffective on human prions.To date, approximately 500 iatrogenic Creutzfeldt-Jakob disease cases have been reported worldwide, most of them resulting from cadaveric dura mater graft and from the administration of prion-contaminated human growth hormone. The unusual resistance of prions to decontamination processes, their large tissue distribution, and the uncertainty about the prevalence of variant Creutzfeldt-Jakob disease (vCJD) in the general population lead to specific recommendations regarding identification of tissue at risk and reprocessing of reusable medical devices, including the use of dedicated treatment for prion inactivation. We previously described an in vitro assay, called Surf-PMCA, which allowed us to classify prion decontamination treatments according to their efficacy on vCJD prions by monitoring residual seeding activity (RSA). Here, we used a transgenic mouse line permissive to vCJD prions to study the correlation between the RSA measured in vitro and the in vivo infectivity. Implantation in mouse brains of prion-contaminated steel wires subjected to different decontamination procedures allows us to demonstrate a good concordance between RSA measured by Surf-PMCA (in vitro) and residual infectivity (in vivo). These experiments emphasize the strength of the Surf-PMCA method as a rapid and sensitive assay for the evaluation of prion decontamination procedures and also confirm the lack of efficacy of several marketed reagents on vCJD prion decontamination.IMPORTANCE Creutzfeldt-Jakob diseases are neurodegenerative disorders for which transmission linked to medical procedures have been reported in hundreds of patients. As prion diseases, they are characterized by an unusual resistance to conventional decontamination processes. Moreover, their large tissue distribution and the ability of prions to attach to many surfaces raised the risk of transmission in health care facilities. It is therefore of major importance that decontamination procedures applied to medical devices before their reprocessing are thoroughly validated for prion inactivation. We previously described an in vitro assay, which allowed us to classify accurately prion decontamination treatments according to their efficacy on variant Creutzfeldt-Jakob disease. The significance of this study is in demonstrating the concordance between previous in vitro results and infectivity studies in transgenic mice. Furthermore, commercial reagents currently used in hospitals were tested by both protocols, and we observed that most of them were ineffective on human prions. ABSTRACTTo date, approximately 500 iatrogenic Creutzfeldt-Jakob disease cases have been reported worldwide, most of them resulting from cadaveric dura mater graft and from the administration of prion-contaminated human growth hormone. The unusual resistance of prions to decontamination processes, their large tissue distribution, and the uncertainty about the prevalence of variant Creutzfeldt-Jakob disease (vCJD) in the general population lead to specific recommendations regarding identification of tissue at risk and reprocessing of reusable medical devices, including the use of dedicated treatment for prion inactivation. We previously described an in vitro assay, called Surf-PMCA, which allowed us to classify prion decontamination treatments according to their efficacy on vCJD prions by monitoring residual seeding activity (RSA). Here, we used a transgenic mouse line permissive to vCJD prions to study the correlation between the RSA measured in vitro and the in vivo infectivity. Implantation in mouse brains of prion-contaminated steel wires subjected to different decontamination procedures allows us to demonstrate a good concordance between RSA measured by Surf-PMCA (in vitro) and residual infectivity (in vivo). These experiments emphasize the strength of the Surf-PMCA method as a rapid and sensitive assay for the evaluation of prion decontamination procedures and also confirm the lack of efficacy of several marketed reagents on vCJD prion decontamination.IMPORTANCE Creutzfeldt-Jakob diseases are neurodegenerative disorders for which transmission linked to medical procedures have been reported in hundreds of patients. As prion diseases, they are characterized by an unusual resistance to conventional decontamination processes. Moreover, their large tissue distribution and the ability of prions to attach to many surfaces raised the risk of transmission in health care facilities. It is therefore of major importance that decontamination procedures applied to medical devices before their reprocessing are thoroughly validated for prion inactivation. We previously described an in vitro assay, which allowed us to classify accurately prion decontamination treatments according to their efficacy on variant Creutzfeldt-Jakob disease. The significance of this study is in demonstrating the concordance between previous in vitro results and infectivity studies in transgenic mice. Furthermore, commercial reagents currently used in hospitals were tested by both protocols, and we observed that most of them were ineffective on human prions. |
| Author | Bélondrade, Maxime Béringue, Vincent Bougard, Daisy Reine, Fabienne Lehmann, Sylvain Torres, Juan Maria Jas-Duval, Christelle Nicot, Simon Fournier-Wirth, Chantal Mayran, Charly Bruyère-Ostells, Lilian Herzog, Laetitia |
| Author_xml | – sequence: 1 givenname: Maxime surname: Bélondrade fullname: Bélondrade, Maxime organization: Pathogenesis and Control of Chronic Infections, Etablissement Français du Sang, INSERM, Université de Montpellier, Montpellier, France – sequence: 2 givenname: Christelle surname: Jas-Duval fullname: Jas-Duval, Christelle organization: VIM INRA, Université Paris-Saclay, Jouy-en-Josas, France – sequence: 3 givenname: Simon surname: Nicot fullname: Nicot, Simon organization: Pathogenesis and Control of Chronic Infections, Etablissement Français du Sang, INSERM, Université de Montpellier, Montpellier, France – sequence: 4 givenname: Lilian surname: Bruyère-Ostells fullname: Bruyère-Ostells, Lilian organization: Pathogenesis and Control of Chronic Infections, Etablissement Français du Sang, INSERM, Université de Montpellier, Montpellier, France – sequence: 5 givenname: Charly surname: Mayran fullname: Mayran, Charly organization: Pathogenesis and Control of Chronic Infections, Etablissement Français du Sang, INSERM, Université de Montpellier, Montpellier, France – sequence: 6 givenname: Laetitia surname: Herzog fullname: Herzog, Laetitia organization: VIM INRA, Université Paris-Saclay, Jouy-en-Josas, France – sequence: 7 givenname: Fabienne surname: Reine fullname: Reine, Fabienne organization: VIM INRA, Université Paris-Saclay, Jouy-en-Josas, France – sequence: 8 givenname: Juan Maria surname: Torres fullname: Torres, Juan Maria organization: Centro de Investigación en Sanidad Animal, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (CISA-INIA), Madrid, Spain – sequence: 9 givenname: Chantal surname: Fournier-Wirth fullname: Fournier-Wirth, Chantal organization: Pathogenesis and Control of Chronic Infections, Etablissement Français du Sang, INSERM, Université de Montpellier, Montpellier, France – sequence: 10 givenname: Vincent orcidid: 0000-0001-6706-5712 surname: Béringue fullname: Béringue, Vincent organization: VIM INRA, Université Paris-Saclay, Jouy-en-Josas, France – sequence: 11 givenname: Sylvain surname: Lehmann fullname: Lehmann, Sylvain organization: CHRU de Montpellier and Université de Montpellier, IRMB, INSERM U1183, Laboratoire de Biochimie Protéomique Clinique, Montpellier, France – sequence: 12 givenname: Daisy orcidid: 0000-0002-8779-9251 surname: Bougard fullname: Bougard, Daisy email: daisy.bougard@efs.sante.fr organization: Pathogenesis and Control of Chronic Infections, Etablissement Français du Sang, INSERM, Université de Montpellier, Montpellier, France daisy.bougard@efs.sante.fr |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31996421$$D View this record in MEDLINE/PubMed https://hal.umontpellier.fr/hal-03116427$$DView record in HAL |
| BookMark | eNpdkktv1DAUhSNUREvpnhWKxAYWKX4kfmyQhmmhRYNAKrC1HOdmxkNiD7ZTNP0B_G4yk1K1XVi2rs_5rh_neXbgvIMse4nRKcZEvOvjZgUBThFipSywfJIdEcplUaGSHNxbH2YnMa4RQpgRxjh7lh1SLCUrCT7K_s59CNDpZL3La0h_AFz-wXodo97m2jX5t-ATWJd_sbH1XWPdMp9vTWdNPus3nW2tmcytD_lPHax2KZ8HGNJNC12Tis_6l6_zMxtBR8jPwHiXdG_d5LpKQ2MhvsietrqLcHI7H2c_Pp5_n18Ui6-fLuezRWEqglLBytZUtKGIEGCEs1oIQznjppQUC1liLXFTS6i0QLpqBKYVY1ULNYiyKVtJj7PLidt4vVabYHsdtsprq_YFH5ZKh2RNB4o2RFcgNKcclZiTGsa-rcC8Eq2ouB5Z7yfWZqh7aAy4FHT3APpwx9mVWvprxaQcPweNgLcTYPXIdjFbqF0NUYzHb-LXeNS-uW0W_O8BYlK9jQa6TjvwQ1SEloJLOY5R-vqRdO2H4MZnHVVMMElLSkYVmlQm-BgDtHcnwEjt8qX6q32-1D5fCu_Ar-5f-M7wP030H1nIz7s |
| CitedBy_id | crossref_primary_10_3390_biom13121788 crossref_primary_10_1016_j_jhin_2020_10_018 crossref_primary_10_1017_S1473550420000397 crossref_primary_10_3390_biom10030405 crossref_primary_10_3390_app11209777 crossref_primary_10_3390_pathogens9110947 crossref_primary_10_1016_S1474_4422_20_30238_6 crossref_primary_10_1371_journal_pone_0304603 crossref_primary_10_1007_s00441_022_03603_2 crossref_primary_10_1016_j_jhin_2022_08_014 crossref_primary_10_1371_journal_pone_0290325 crossref_primary_10_1038_s41598_022_15105_w crossref_primary_10_1371_journal_ppat_1012175 crossref_primary_10_1038_s41598_022_26201_2 crossref_primary_10_1111_1348_0421_13092 crossref_primary_10_3390_v14071390 crossref_primary_10_1038_s41582_021_00488_7 crossref_primary_10_3389_fbioe_2020_591024 crossref_primary_10_3389_fbioe_2020_589182 |
| Cites_doi | 10.1371/journal.pone.0146833 10.1086/502392 10.3171/2016.5.FOCUS15126 10.1126/scitranslmed.aag1257 10.1073/pnas.0605608103 10.1371/journal.pone.0089722 10.1371/journal.ppat.1000029 10.1016/s0140-6736(01)05403-4 10.1146/annurev.neuro.24.1.519 10.1371/journal.pone.0069632 10.1371/journal.pone.0015626 10.1111/j.1471-4159.2011.07399.x 10.1371/journal.pone.0001419 10.1073/pnas.95.23.13363 10.1016/S0140-6736(04)16810-4 10.1038/nmeth0308-211 10.1074/jbc.M407006200 10.1038/s41586-018-0790-y 10.1126/scitranslmed.aam7785 10.1128/mBio.02095-18 10.1099/0022-1317-77-4-811 10.1128/JVI.79.9.5259-5271.2005 10.1128/JVI.01118-14 10.1007/BF03402121 10.1128/JVI.01356-06 10.1126/scitranslmed.aaf6188 10.1074/jbc.M603964200 10.1056/NEJMc1610003 10.1128/JVI.80.1.322-331.2006 10.1056/NEJMoa1404401 10.1128/JVI.00144-16 10.1038/35081095 10.3201/eid2407.172105 10.1073/pnas.96.26.15137 10.1128/JVI.02387-09 10.3201/eid2309.161948 10.1038/s41598-017-10922-w 10.1126/science.6801762 10.1128/mBio.00829-13 10.1016/j.mimet.2007.06.005 10.1016/j.ebiom.2016.08.033 10.1074/jbc.M113.470328 10.1099/vir.0.80484-0 10.1086/598342 10.1038/ncomms1730 10.1056/NEJMoa030351 10.1007/BF03401958 10.1128/JVI.06134-11 10.1073/pnas.1111255108 10.1038/emboj.2008.181 10.1371/journal.ppat.1000206 10.1371/journal.ppat.1002128 10.1016/j.jhin.2009.03.024 10.1016/S0140-6736(88)92276-3 10.3201/eid2001.130353 10.3201/eid1806.120116 |
| ContentType | Journal Article |
| Copyright | Copyright © 2020 Bélondrade et al. Copyright © 2020 Bélondrade et al. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Attribution Copyright © 2020 Bélondrade et al. 2020 Bélondrade et al. |
| Copyright_xml | – notice: Copyright © 2020 Bélondrade et al. – notice: Copyright © 2020 Bélondrade et al. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Attribution – notice: Copyright © 2020 Bélondrade et al. 2020 Bélondrade et al. |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7X7 7XB 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M7P PIMPY PQEST PQQKQ PQUKI PRINS 7X8 1XC VOOES 5PM DOA |
| DOI | 10.1128/msphere.00649-19 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection AUTh Library subscriptions: ProQuest Central ProQuest Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection (Proquest) (PQ_SDU_P3) ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) Biological Science Database Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE CrossRef MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: AUTh Library subscriptions: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| DocumentTitleAlternate | Testing Methods for vCJD Decontamination |
| EISSN | 2379-5042 |
| Editor | Zabel, Mark D. |
| Editor_xml | – sequence: 1 givenname: Mark D. surname: Zabel fullname: Zabel, Mark D. |
| ExternalDocumentID | oai_doaj_org_article_3d2a5e8a73704172bed30f81758f857a oai_HAL_hal_03116427v1 10_1128_mSphere_00649_19 31996421 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: ; grantid: P79 PrionMDsecure |
| GroupedDBID | 0R~ 3V. 53G 5VS 7X7 8FE 8FH 8FI 8FJ AAFWJ AAUOK ABUWG ADBBV AFKRA AFPKN ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI CCPQU CGR CUY CVF DIK EBS ECM EIF FRP FYUFA GROUPED_DOAJ H13 HCIFZ HMCUK HYE KQ8 LK8 M48 M7P M~E NPM O9- OK1 PGMZT PIMPY PQQKQ PROAC R9- RHF RHI RPM RSF UKHRP AAYXX CITATION 7XB 8FK AZQEC DWQXO GNUQQ K9. PQEST PQUKI PRINS 7X8 1XC VOOES 5PM |
| ID | FETCH-LOGICAL-c520t-64fc53d3022e6276b88c3767c49318941a91db9e5a80a5d8135665febe84d4f93 |
| IEDL.DBID | RPM |
| ISSN | 2379-5042 |
| IngestDate | Tue Oct 22 15:12:14 EDT 2024 Tue Sep 17 21:07:04 EDT 2024 Thu Sep 12 06:30:50 EDT 2024 Sat Oct 26 04:35:24 EDT 2024 Mon Oct 28 14:26:16 EDT 2024 Fri Aug 23 01:13:04 EDT 2024 Tue Oct 29 09:11:55 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | bioassay prion variant Creutzfeldt-Jakob disease decontamination PMCA |
| Language | English |
| License | Copyright © 2020 Bélondrade et al. Attribution: http://creativecommons.org/licenses/by This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c520t-64fc53d3022e6276b88c3767c49318941a91db9e5a80a5d8135665febe84d4f93 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Maxime Bélondrade, Christelle Jas-Duval, and Simon Nicot contributed equally to this work. Author order was determined alphabetically. Citation Bélondrade M, Jas-Duval C, Nicot S, Bruyère-Ostells L, Mayran C, Herzog L, Reine F, Torres JM, Fournier-Wirth C, Béringue V, Lehmann S, Bougard D. 2020. Correlation between bioassay and protein misfolding cyclic amplification for variant Creutzfeldt-Jakob disease decontamination studies. mSphere 5:e00649-19. https://doi.org/10.1128/mSphere.00649-19. |
| ORCID | 0000-0001-6706-5712 0000-0002-8779-9251 0000-0001-6118-2918 0000-0001-6117-562X 0000-0003-0262-5138 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992370/ |
| PMID | 31996421 |
| PQID | 2368693432 |
| PQPubID | 2045592 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_3d2a5e8a73704172bed30f81758f857a pubmedcentral_primary_oai_pubmedcentral_nih_gov_6992370 hal_primary_oai_HAL_hal_03116427v1 proquest_miscellaneous_2348799879 proquest_journals_2368693432 crossref_primary_10_1128_mSphere_00649_19 pubmed_primary_31996421 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-02-26 |
| PublicationDateYYYYMMDD | 2020-02-26 |
| PublicationDate_xml | – month: 02 year: 2020 text: 2020-02-26 day: 26 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Washington – name: 1752 N St., N.W., Washington, DC |
| PublicationTitle | mSphere |
| PublicationTitleAlternate | mSphere |
| PublicationYear | 2020 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| References | e_1_3_2_26_2 e_1_3_2_49_2 e_1_3_2_28_2 e_1_3_2_41_2 e_1_3_2_20_2 e_1_3_2_43_2 e_1_3_2_22_2 e_1_3_2_45_2 e_1_3_2_24_2 e_1_3_2_47_2 e_1_3_2_9_2 World Health Organization (e_1_3_2_19_2) 2006 e_1_3_2_16_2 e_1_3_2_37_2 e_1_3_2_7_2 e_1_3_2_39_2 e_1_3_2_54_2 e_1_3_2_10_2 e_1_3_2_31_2 e_1_3_2_52_2 e_1_3_2_5_2 e_1_3_2_12_2 e_1_3_2_33_2 e_1_3_2_58_2 e_1_3_2_3_2 e_1_3_2_14_2 e_1_3_2_35_2 e_1_3_2_56_2 e_1_3_2_50_2 e_1_3_2_27_2 e_1_3_2_48_2 e_1_3_2_29_2 e_1_3_2_40_2 e_1_3_2_21_2 e_1_3_2_42_2 e_1_3_2_23_2 e_1_3_2_44_2 e_1_3_2_25_2 e_1_3_2_46_2 e_1_3_2_15_2 e_1_3_2_38_2 e_1_3_2_8_2 e_1_3_2_17_2 e_1_3_2_59_2 e_1_3_2_6_2 World Health Organization (e_1_3_2_18_2) 1999 e_1_3_2_30_2 e_1_3_2_53_2 e_1_3_2_32_2 e_1_3_2_51_2 e_1_3_2_11_2 e_1_3_2_34_2 e_1_3_2_57_2 e_1_3_2_4_2 e_1_3_2_13_2 e_1_3_2_36_2 e_1_3_2_55_2 e_1_3_2_2_2 |
| References_xml | – ident: e_1_3_2_33_2 doi: 10.1371/journal.pone.0146833 – ident: e_1_3_2_25_2 doi: 10.1086/502392 – ident: e_1_3_2_12_2 doi: 10.3171/2016.5.FOCUS15126 – ident: e_1_3_2_8_2 doi: 10.1126/scitranslmed.aag1257 – ident: e_1_3_2_38_2 doi: 10.1073/pnas.0605608103 – ident: e_1_3_2_41_2 doi: 10.1371/journal.pone.0089722 – ident: e_1_3_2_56_2 doi: 10.1371/journal.ppat.1000029 – ident: e_1_3_2_7_2 doi: 10.1016/s0140-6736(01)05403-4 – ident: e_1_3_2_2_2 doi: 10.1146/annurev.neuro.24.1.519 – volume-title: WHO guidelines on tissue infectivity distribution in transmissible spongiform encephalopathies year: 2006 ident: e_1_3_2_19_2 contributor: fullname: World Health Organization – ident: e_1_3_2_50_2 doi: 10.1371/journal.pone.0069632 – ident: e_1_3_2_51_2 doi: 10.1371/journal.pone.0015626 – ident: e_1_3_2_55_2 doi: 10.1111/j.1471-4159.2011.07399.x – ident: e_1_3_2_47_2 doi: 10.1371/journal.pone.0001419 – ident: e_1_3_2_4_2 doi: 10.1073/pnas.95.23.13363 – ident: e_1_3_2_20_2 doi: 10.1016/S0140-6736(04)16810-4 – ident: e_1_3_2_28_2 doi: 10.1038/nmeth0308-211 – ident: e_1_3_2_59_2 doi: 10.1074/jbc.M407006200 – ident: e_1_3_2_58_2 doi: 10.1038/s41586-018-0790-y – ident: e_1_3_2_11_2 doi: 10.1126/scitranslmed.aam7785 – ident: e_1_3_2_10_2 doi: 10.1128/mBio.02095-18 – ident: e_1_3_2_14_2 doi: 10.1099/0022-1317-77-4-811 – ident: e_1_3_2_44_2 doi: 10.1128/JVI.79.9.5259-5271.2005 – ident: e_1_3_2_46_2 doi: 10.1128/JVI.01118-14 – ident: e_1_3_2_17_2 doi: 10.1007/BF03402121 – ident: e_1_3_2_48_2 doi: 10.1128/JVI.01356-06 – ident: e_1_3_2_9_2 doi: 10.1126/scitranslmed.aaf6188 – ident: e_1_3_2_36_2 doi: 10.1074/jbc.M603964200 – ident: e_1_3_2_52_2 doi: 10.1056/NEJMc1610003 – ident: e_1_3_2_23_2 doi: 10.1128/JVI.80.1.322-331.2006 – ident: e_1_3_2_32_2 doi: 10.1056/NEJMoa1404401 – ident: e_1_3_2_57_2 doi: 10.1128/JVI.00144-16 – ident: e_1_3_2_29_2 doi: 10.1038/35081095 – ident: e_1_3_2_30_2 doi: 10.3201/eid2407.172105 – ident: e_1_3_2_40_2 doi: 10.1073/pnas.96.26.15137 – ident: e_1_3_2_45_2 doi: 10.1128/JVI.02387-09 – ident: e_1_3_2_42_2 doi: 10.3201/eid2309.161948 – ident: e_1_3_2_31_2 doi: 10.1038/s41598-017-10922-w – volume-title: WHO infection control guidelines for transmissible spongiform encephalopathies year: 1999 ident: e_1_3_2_18_2 contributor: fullname: World Health Organization – ident: e_1_3_2_3_2 doi: 10.1126/science.6801762 – ident: e_1_3_2_35_2 doi: 10.1128/mBio.00829-13 – ident: e_1_3_2_26_2 doi: 10.1016/j.mimet.2007.06.005 – ident: e_1_3_2_6_2 doi: 10.1016/j.ebiom.2016.08.033 – ident: e_1_3_2_43_2 doi: 10.1074/jbc.M113.470328 – ident: e_1_3_2_21_2 doi: 10.1099/vir.0.80484-0 – ident: e_1_3_2_24_2 doi: 10.1086/598342 – ident: e_1_3_2_49_2 doi: 10.1038/ncomms1730 – ident: e_1_3_2_5_2 doi: 10.1056/NEJMoa030351 – ident: e_1_3_2_16_2 doi: 10.1007/BF03401958 – ident: e_1_3_2_37_2 doi: 10.1128/JVI.06134-11 – ident: e_1_3_2_54_2 doi: 10.1073/pnas.1111255108 – ident: e_1_3_2_34_2 doi: 10.1038/emboj.2008.181 – ident: e_1_3_2_27_2 doi: 10.1371/journal.ppat.1000206 – ident: e_1_3_2_53_2 doi: 10.1371/journal.ppat.1002128 – ident: e_1_3_2_22_2 doi: 10.1016/j.jhin.2009.03.024 – ident: e_1_3_2_15_2 doi: 10.1016/S0140-6736(88)92276-3 – ident: e_1_3_2_39_2 doi: 10.3201/eid2001.130353 – ident: e_1_3_2_13_2 doi: 10.3201/eid1806.120116 |
| SSID | ssj0001626676 |
| Score | 2.2726452 |
| Snippet | To date, approximately 500 iatrogenic Creutzfeldt-Jakob disease cases have been reported worldwide, most of them resulting from cadaveric dura mater graft and... Creutzfeldt-Jakob diseases are neurodegenerative disorders for which transmission linked to medical procedures have been reported in hundreds of patients. As... ABSTRACTTo date, approximately 500 iatrogenic Creutzfeldt-Jakob disease cases have been reported worldwide, most of them resulting from cadaveric dura mater... ABSTRACT To date, approximately 500 iatrogenic Creutzfeldt-Jakob disease cases have been reported worldwide, most of them resulting from cadaveric dura mater... |
| SourceID | doaj pubmedcentral hal proquest crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| SubjectTerms | Animals bioassay Bioassays Bovine spongiform encephalopathy Brain Cadavers Caustic soda Creutzfeldt-Jakob disease Creutzfeldt-Jakob Syndrome - etiology Creutzfeldt-Jakob Syndrome - pathology Decontamination Decontamination - methods Dura mater Equipment Contamination Female Growth hormones Humans Iatrogenic Disease Infectivity Life Sciences Medical equipment Mice Mice, Transgenic Neurodegenerative diseases Otolaryngology Physiology PMCA prion Prion protein Prion Proteins - chemistry Prions Protein folding Protein seeding Proteins Proteostasis Deficiencies - pathology Sodium Surgical apparatus & instruments Therapeutics and Prevention Transgenic animals Transgenic mice variant Creutzfeldt-Jakob disease Wire |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQJSQuiPIMLZWLuHCImvjt47JttaoAIUFRb5YT2-qqJYtKFmn5AfxuZuJ0tQsHLr3GjmPNI_ON_XlMyBvVNhHSYzyNo2IpTGvKxiheJiXAmZhMKrN8P6rZuTi7kBcbV30hJyyXB86CO-KBeRmN11xXAqJtEwOvkoGoZ5KROkOjym4kU8PqCuB0pdf7kswcffuMx_Qj8riELbGwzkYcGsr1Q3S5RDLkv0jzb8LkRgQ6fUQejtCRTvKUd8m92D0m9_Nlkqsn5PcUL9rI1DY60q8otAI69ivqu0A_YU2GeUc_zAGqDptOdLpqr-ctnSCvPI3LdxRwLP0KOTQInU5v4rL_leJ16Mszf7Vo6HHe0qHHmEr3Hqk0w1sjI_EpOT89-TKdleMtC2UrWdWXSqRWchAqY1ExrRpjWizx0goL_m5F7W0dGhulN5WXwdQcEKBMoHwjgkiWPyM73aKLLwiNIQECTIoFxYQ2ycagmyQgqeK8ZSEV5O2tzN33XEzDDUkIM27Ujxv042pbkHeolHU_LIM9PADjcKNxuP8ZR0Feg0q3xphN3jt8Bj8zyBSZ_lkXZP9W42504B-OcWWUxVO3BTlcN4Pr4X6K7-JiiX0g24N0VcNkn2cDWX-KI7tbMBhcb5nO1ly2W7r55VDeW1kA3bp6eRcC2CMPGC4Q4Bl8tU92-ptlfAUoqm8OBof5AxmSHGs priority: 102 providerName: Directory of Open Access Journals – databaseName: AUTh Library subscriptions: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZgKyQuiDeBggziwiHqru34cULbbatVBVUFFPUWOX60K0pStlmk5Qfwu5lJvNsuSFzjPByPx_5m5vMMIW-lqwKYx3gaR4ZcaKfzSkueRylAmVgRZc_yPZLTE3F4Wpwmh9tVolWu1sRuofaNQx_5DuNSS4PHIN9f_sixahRGV1MJjdtki4GlwAZka3f_6PjTtZcF8LpU6_gk0zvfP-Nx_YB8LmFyTLBzYz_q0vbDLnOOpMh_EeffxMkbO9HBfXIvQUg67mX-gNwK9UNypy8quXxEfk-w4EZPcaOJhkWhFVCyXVJbe3qMuRlmNf04A8jaBZ_oZOkuZo6OkV8ekxuPAp6lX8GWhsGnk3lYtL9iuPBtfmi_NRXd60M7dA9N6tYipaZ7KjETH5OTg_0vk2meqi3krmDDNpciuoJ7Dpt6kEzJSmuHqV6cMKD3RoysGfnKhMLqoS28HnFAgkWESaCFF9HwJ2RQN3V4RmjwEZBglMxLJpSOJnhVRQHGFeeO-ZiRd6sxLy_7pBplZ4wwXSb5lJ18ypHJyC4KZX0fpsPuLjTzszJpV8k9s0XQVnE1FADJqgD_ETVAIx11oWxG3oBIN94xHX8o8RosamAxMvVzlJHtlcTLpMhX5fW0y8jrdTOoIMZVbB2aBd4DVh-YrQo6-7SfIOtPcWR5CwYvVxtTZ6Mvmy317LxL8y0NgG81fP7_br0gdxm6APCUvdwmg3a-CC8BJ7XVq6QMfwB2DBXp priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access(OpenAccess) dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lj9MwELbQItBeEG8CCzKIC4dA47cPCJUuq2oFCAmK9mY5sc1WlBRKiig_gN_NTJIWAnvgGufhZGbi77O_GRPyUFVlBHqM2Tgq5sJUJi-N4nlSAoKJyaQ6le9rNZ2J4xN58js9uv-AX8-kdrif1Gy1ePz9y-YZBPzTLgHGPPn0FjPwI0q0hM2xBuh5hmW5UMjXg_12xgWwu9K7tcozLtwnFzmqcgUrBsNUW80fBp9T1Er-C0T_1lP-MUAdXSaXemRJx50rXCHnYn2VXOj2mtxcIz8nuA9Hp3yjvTqLQiuAZ7-hvg70DZZsmNf01RyQbLsmRSebajGv6Bhl56mf3aMAc-l7oNhgEzpZxXXzI8VFaPJj_3FZ0sNuxYceItNuPCpt2qt6weJ1Mjt68W4yzftNGPJKslGTK5EqyQOHsT4qplVpTIUVYCph4XdgReFtEUobpTcjL4MpOABEmcA3jAgiWX6D7NXLOt4iNIYEADEpFhQT2iQbgy6TAM7FecVCysij7Td3n7taG67lKMy43lSuNZUrbEaeo1F252GV7PbAcvXB9UHneGBeRuM11yMBSK2M8B7JAGIyyUjtM_IATDq4x3T80uEx-NcBkWT6W5GRg63F3dY9HePKKItJuRm5v2uGyMTlFl_H5RrPATIIbFZDZ292DrJ71NbNMqIHrjPoy7Clnp-21b-VBUyuR7f_p-93yD7D-QFMwVcHZK9ZreNdAFFNea-NjV96AxwX priority: 102 providerName: Scholars Portal |
| Title | Correlation between Bioassay and Protein Misfolding Cyclic Amplification for Variant Creutzfeldt-Jakob Disease Decontamination Studies |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31996421 https://www.proquest.com/docview/2368693432 https://www.proquest.com/docview/2348799879 https://hal.umontpellier.fr/hal-03116427 https://pubmed.ncbi.nlm.nih.gov/PMC6992370 https://doaj.org/article/3d2a5e8a73704172bed30f81758f857a |
| Volume | 5 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLW2ISReEN8ERmUQLzxkbRzHdh6zbFM16KiAor5Fjj9YRJtOJUUqP4DfzbWTVCu88dJIcdK6uefG59rnXiP0lqnSQHjssnGYCalQIiwFi0PLKDgTSSxrVb5XbDyjl_NkfoCSPhfGi_ZVWZ3Ui-VJXV17beXNUg17ndhwOslZCrSEj4aH6BAAeitE9xMrQNEZ3y1JEjFcfnYZ-sZJuGgaRq5QaOzEt5REe6ORL9oPY8y1k0T-yzf_lk3eGocuHqD7HYHEWdvRh-jA1I_Q3XZLye1j9Dt32220AjfcibAwtAJHllssa42nrjJDVeNJBYTVLz3hfKsWlcKZU5fbbhIPA5vFXyGShkeP87XZNL-sWegmvJTfVyU-axd28JkLqBvpBDX-rk6X-ATNLs6_5OOw22shVAkZNSGjViWxjmFIN4xwVgqhXKEXRVPw-pRGMo10mZpEipFMtIhi4IGJBQgIqqlN46foqF7V5jnCRlvggZYRzQjlwqZG89JSCK3iWBFtA_Suf-bFTVtSo_ChCBFFZ6rCm6qI0gCdOqPsrnPFsP2J1fpb0UGiiDWRiRGSAyYoELLSwP-wAoiRsCLhMkBvwKR73zHOPhTuHLzSIF4k_GcUoOPe4kXnxj8KEjPBUpd7G6DXu2ZwQLeqImuz2rhrIOaDoJVDZ5-1ANn9VA-zAPE96Oz1Zb8FMO-LfHcYf_Hfd75E94ibG3Dp9-wYHTXrjXkFBKopB-A2cz5Ad7Js9vE9HE_Pr6afBn46Aj4nVAy8S_0BE8EjZw |
| link.rule.ids | 230,315,730,783,787,867,888,2109,12070,21402,24332,27938,27939,31733,31734,33758,33759,43324,43819,53806,53808,74081,74638 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgCMEL4nMEBhjECw_RGtuxnSdUOqYyugmJDfXNcmKbVYxkdClS-QP4u7lL3G4Fidc4H47PZ__u7uc7Ql7LqvRgHuNpHOlToSudllryNEgBysTyIHuW75Ecn4iDaT6NDreLSKtcrYndQu2aCn3ku4xLLQs8Bvn2_EeKVaMwuhpLaFwnNzAPF-bOV1N16WMBtC7VOjrJ9O73z3hY3yObSxQppte5sht1SfthjzlFSuS_ePNv2uSVfWj_LrkTASQd9hK_R675-j652ZeUXD4gv0dYbqMnuNFIwqLQChjZLqmtHf2EmRlmNT2cAWDtQk90tKzOZhUdIrs8RCceBTRLv4AlDUNPR3O_aH8Ff-ba9MB-a0q61wd26B4a1K1FQk33VOQlPiQn---PR-M01lpIq5wN2lSKUOXccdjSvWRKllpXmOilEgVofSEyW2SuLHxu9cDmTmcccGAeYApo4UQo-COyVTe1f0yodwFwYJDMSSaUDoV3qgwCTCvOK-ZCQt6sxtyc9yk1TGeKMG2ifEwnH5MVCXmHQlnfh8mwuwvN_KuJumW4Yzb32iquBgIAWenhP4IGYKSDzpVNyCsQ6cY7xsOJwWuwpIG9yNTPLCE7K4mbqMYX5nLSJeTluhkUEKMqtvbNAu8Bmw-MVgWd3e4nyPpTHDnegsHL1cbU2ejLZks9O-2SfMsCoLcaPPl_t16QW-Pjw4mZfDj6-JTcZugMwPP2codstfOFfwaIqS2fd2rxBw1AF3Q |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fb9MwELagE4gXxG8KAwzihYeore3YzhPq2lVljKoChvZmObHNqm3p6FKk8gfwd3OXuN0KEq9x4ji5O_s73-c7Qt7KIvfgHuNpHOkToQud5FryJEgBxsTSIBuW70SOj8TBcXoc-U-XkVa5nhPridrNC9wj7zAutczwGGQnRFrEdDh6f_EjwQpSGGmN5TRukh0lQKtaZGdvfzL9fLXjAthdqk2skunO-Rc8uu-R2yWyBJPtXFub6hT-sOKcIEHyX_T5N4ny2qo0ukfuRjhJ-43875MbvnxAbjUFJlcPye8BFt9o6G40UrIotAJititqS0enmKdhVtJPM4CvdSCKDlbF2aygfeSah7ilRwHb0m_gV4Mg6GDhl9Wv4M9clRzY03lOh02Yhw7Rva4s0mvqpyJL8RE5Gu1_HYyTWHkhKVLWrRIpQpFyx2GB95IpmWtdYNqXQmQwB2SiZ7OeyzOfWt21qdM9DqgwDaAQWjgRMv6YtMp56Z8S6l0AVBgkc5IJpUPmncqDAEeL84K50Cbv1v_cXDQJNkztmDBtonxMLR_Ty9pkD4WyuQ9TY9cX5ovvJlqa4Y7Z1GuruOoKgGe5h-8IGmCSDjpVtk3egEi3-hj3Dw1egwkOvEemfvbaZHctcRON-tJcqWCbvN40gzlijMWWfr7Ee8ADBBdWwWCfNAqyeRVHxrdg0LnaUp2tsWy3lLOTOuW3zACIq-6z_w_rFbkNNmEOP0w-Pid3GO4M4OF7uUta1WLpXwB8qvKX0S7-ANVoHRc |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Correlation+between+Bioassay+and+Protein+Misfolding+Cyclic+Amplification+for+Variant+Creutzfeldt-Jakob+Disease+Decontamination+Studies&rft.jtitle=mSphere&rft.au=B%C3%A9londrade%2C+Maxime&rft.au=Jas-Duval%2C+Christelle&rft.au=Nicot%2C+Simon&rft.au=Bruy%C3%A8re-Ostells%2C+Lilian&rft.date=2020-02-26&rft.pub=American+Society+for+Microbiology&rft.eissn=2379-5042&rft.volume=5&rft.issue=1&rft_id=info:doi/10.1128%2FmSphere.00649-19&rft_id=info%3Apmid%2F31996421&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=oai_HAL_hal_03116427v1 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2379-5042&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2379-5042&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2379-5042&client=summon |